Could a probiotic cream shield cancer patients from radiation burns?

NCT ID NCT07635277

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe and tolerable, and to measure how many patients develop moderate to severe skin reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
inactivated Akkermansia muciniphila bacteria (topical preparation)
What this could lead to
If it works, this could point toward a simple cream to prevent or reduce skin damage from radiation therapy.
What could go wrong
This is a very early Phase 1 trial with only 40 people, so it is mainly checking safety. It may not prove effective, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jintang County First People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610400, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.